UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
i ATI PHYSICAL THERAPY, INC.
(Exact name of registrant as specified in its charter)
i Delaware
|
|
i 85-1408039
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
i 790 Remington Boulevard
i Bolingbrook, i Illinois
|
|
i 60440
|
(Address of principal executive offices)
|
|
(Zip Code)
|
( i 630)
i 296-2223
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following
provisions:
i ☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
i ☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
i ☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
i ☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class
|
|
Trading Symbol
|
|
Name of Each Exchange on Which Registered
|
i Class A Common Stock, $0.0001 par value
|
|
i ATIP
|
|
New York Stock Exchange
|
|
|
|
|
|
i Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share
|
|
i ATIP WS
|
|
New York Stock Exchange
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On
March 2, 2023, ATI Physical Therapy, Inc. (the
“Company”) filed a petition in the Delaware Court of Chancery (the
“Court of Chancery”) pursuant to Section 205 of the
Delaware General Corporation Law (
“DGCL”), seeking validation of an amendment to its
certificate of incorporation increasing the authorized shares of Class A common stock of
the Company (as further described below) and the shares issued pursuant
thereto.
At a special meeting of the stockholders of
the Company held on
June 15, 2021 (the
“Special Meeting”), a majority of the then-outstanding shares of
the Company’s Class
A common stock and Class F common stock, voting together as a single class, voted to approve
the Company’s Second Amended and Restated
Certificate of Incorporation, which, among other things, increased the authorized shares of
the Company’s Class
A common stock from 200,000,000 shares to 450,000,000 shares (the
“Class A Increase Amendment”). Notwithstanding the fact that the proxy statement relating to the Special Meeting did not disclose that a separate vote of the Class A common stock
was required, a majority of the then-outstanding shares of Class A common stock voted in favor of the Class A Increase Amendment.
A recent decision of the Court of Chancery has created uncertainty regarding the validity of the Class A Increase Amendment and whether a separate vote of the majority
of the then-outstanding shares of Class A common stock would have been required under Section 242(b)(2) of the DGCL.
The Company continues to believe that a separate vote of Class A common stock was not required to approve the Class A Increase Amendment. However, in light of the
recent Court of Chancery decision,
the Company filed a petition in the Court of Chancery pursuant to Section 205 of the DGCL seeking validation of the Class A Increase Amendment and the shares issued pursuant thereto to resolve any uncertainty
with respect to those matters. Section 205 of the DGCL permits the Court of Chancery, in its discretion, to validate potentially defective corporate acts and stock after considering a variety of factors.
While
the Company believes that a separate vote of Class A common stock was not required to approve the Class A Increase Amendment at the Special Meeting, and therefore
that all of the currently outstanding shares of Class A common stock of
the Company are validly issued, if
the Company is not successful in the Section 205 proceeding, the uncertainty with respect to
the Company’s capitalization resulting from
the Court of Chancery’s decision referenced above could have a material adverse effect on
the Company, including its ability to complete financing transactions, until the underlying issues are definitively resolved.
On
March 3, 2023, the Court of Chancery granted the motion to expedite and set a hearing date for the petition to be heard. The hearing has been set for
March 17,
2023 at 10:20 a.m. Eastern Time at the Leonard L. Williams Justice Center, 500 North King Street,
Wilmington,
Delaware 19801. As ordered by the Court of Chancery,
the Company is filing the petition with this Current Report on Form 8-K, a copy
of which is attached hereto as Exhibit 99.1.
This Form 8-K constitutes notice of the hearing. If any stockholder of
the Company wishes to express a position on the petition, such stockholders of
the Company may
(i) appear at the hearing or (ii) file a written submission with the Register in Chancery, Leonard L. Williams Justice Center, 500 North King Street,
Wilmington,
Delaware 19801, referring to the case caption,
In re ATI Physical Therapy, Inc., C.A. No. 2023-0265-LWW (Del. Ch.), in advance of the hearing. Any such written submission should also be emailed to
the Company’s counsel, Kevin M.
Gallagher, of Richards, Layton & Finger, P.A. at
gallagher@rlf.com.
Forward-Looking Statements
This current report on Form 8-K (this
“Current Report”) includes statements that are not historical facts and are forward-looking statements for purposes of the safe
harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of the words such as
“believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,”
“expect,” “should,” “would,” “plan,” “project,” “forecast,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” “target” or similar expressions that predict or indicate future events or trends or that are not statements of historical
matters. These statements are based on various assumptions, whether or not identified in this Current Report, and on the current expectations of
the Company’s management and are not predictions of actual performance. These forward-looking
statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and
circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of
the Company.
With respect to the matters addressed in this Current Report, no assurances can be made regarding the outcome of
the Company’s proceeding pursuant to Section 205 of the
DGCL. The Section 205 proceeding is subject to inherent uncertainties and is beyond
the Company’s control and may not result in timely resolution of the uncertainty regarding
the Company’s capitalization, if at all. If
the Company is unsuccessful
in the Section 205 proceeding, it could have a material adverse effect on
the Company.
The Company cautions you that these forward-looking statements are subject to numerous risk and uncertainties, most of which are difficult to predict and many of which
are beyond the control of
the Company. Additional risks and uncertainties that could affect
the Company and its financial results are included under the captions
“Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operations” in
the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the
“SEC”) on
November 8, 2022, which is available on
the Company’s
website at
investors.atipt.com and on the SEC’s
website at
www.sec.gov. Additional information will also be set forth in other filings that
the Company
makes with the SEC from time to time. All forward-looking statements in this Current Report are based on information available to
the Company as of the date hereof, and
the Company assumes no obligation to update the forward-looking statements
provided to reflect events that occur or circumstances that exist after the date on which they were made, except as required by applicable law.
Item 9.01. |
Financial Statements and Exhibits.
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
Petition of ATI Physical Therapy, Inc. Pursuant to 8 Del. C. § 205.
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
ATI Physical Therapy, Inc.
|
|
|
|
|
By:
|
/s/ Joseph Jordan
|
|
Name:
|
|
|
Title:
|
Chief Financial Officer
|